The non-exclusive agreement provides Funakoshi with the rights to distribute in Japan.
Among the Standardized RT-PCR reagents (StaRT-PCR) based research molecular tools are kits for chronic myelogenous leukemia, lung cancer risk prediction and inflammation/rheumatoid arthritis. The reagents include a selection of more than 600 StaRT-PCR internal standards.
Jonathan Rowe, COO of Gene Express, said: “The partnership between Funakoshi and Gene Express is extremely valuable as Funakoshi has the experience and capability to bring Gene Express’s patented standardized gene expression technology to Japanese researchers. We are confident that the Gene Express tests and reagents will be widely accepted in the Japanese research market.”